SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " drug " 1,592 found 🔀 AI-powered Shuffle
Anthropic launches Claude Science for pharma researchers
Anthropic had made a big life sciences play with the launch of Claude Science, an AI 'workbench' for researchers involved in drug discovery.
Hospital sued after drug addict nurse allegedly causes death of two patients
An emergency department nurse at Heritage Valley Sewickley Hospital is accused of stealing drugs and neglecting patients, causing at least two fatalities. A lawsuit filed by two whistleblowers further alleges that hospital leadership covered for the drug-dependent nurse.
Anthropic Launches Claude Science to Court Pharma Ahead of IPO
Anthropic unveiled Claude Science, an AI workbench designed to run — not just assist with — pharma research. The company is seeking to build out its customer base in the pharma sector as it deepens its healthcare push ahead of a widely anticipated IPO.
5 things to know about an emerging drug-resistant fungus now putting hospitals at risk of outbreaks
Memo to health execs: If your hospital hasn’t had a C. auris scare yet, odds are quite high that it soon will.
Anthropic unveils drug discovery plans alongside Claude Science, an AI tool for drugmakers
At an event on Tuesday, the AI heavyweight said it plans to target "neglected" diseases.
Researchers say Anthropic’s Claude Science will boost drug discovery
Anthropic's Claude Science aims to speed up drug discovery. Northeastern scientists weigh in on what it could mean for their research.
Western Pa. nurse accused in lawsuit of causing 2 patient deaths, stealing drugs
A federal lawsuit accuses Heritage Valley Health System and staff members of enabling alleged crimes by emergency department nurse Nolan Chismire, including drug theft, false insurance claims, and failures in patient care allegedly linked to two deaths.
Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare
Anthropic will start an internal drug discovery program, part of a new push to sell artificial intelligence tools to drugmakers.
Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare
Anthropic will start an internal drug discovery program, part of a new push to sell artificial intelligence tools to drugmakers.
Holland & Knight Health Dose: June 30, 2026 | Insights
Senate Committee on Health, Employment, Labor, and Pensions (HELP) Chairman Bill Cassidy released a discussion draft making changes to the 340B Drug Pricing Program.
Ozempic Might Be Making Your Team Less Driven. Here’s the Science
New reports on GLP-1 drugs and the brain’s “wanting” system have direct implications for how leaders motivate, reward, build teams, and sustain culture.
Top GLP-1 prescription indications include sleep apnea, depression and kidney disease, study finds
A report from Trilliant Health looking at payer data found that, as prescriptions for the popular weight loss drugs spike, so rises the number of approved benefits.
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of unapproved drugs popular with followers of Robert F. Kennedy Jr.
Databricks and Nvidia Launch Genesis Workbench for AI Scientists
AI is becoming an increasingly important tool for drug discovery. However, for many pharmaceutical and biotech companies, the challenge isn’t finding more powerful models. It’s getting existing models to work […]
GLP-1s 101: What the science says about weight loss, side effects, safety
We asked Stanford Medicine experts to break down everything you need to know about the drugs known as GLP-1s, semaglutide, Ozempic, Wegovy, Zepbound and many more.
Medicare will start covering weight-loss drugs on July 1 for the first time.
Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.
Mental health medications can cause heat sensitivity
Some drugs can impair the body’s ability to cool itself and require extra self-care.
Google Cloud to Offer Specialist AI Models for Science Research
Alphabet Inc.’s Google will start offering specialist artificial intelligence models from software company SandboxAQ through its cloud service, expanding enterprise and research access to technology designed to accelerate drug discovery, materials science and semiconductor manufacturing.
Medicare will start covering weight-loss drugs on July 1 for the first time. Here’s what you need to know
Millions of Medicare enrollees will gain their first-ever coverage for drugs for weight loss under a temporary pilot program that launches July 1.
Medicare is about to cover GLP-1 drugs for weight loss. Here’s what to know.
The Trump administration will launch its pilot program on Wednesday. It lasts 18 months, and estimated costs to taxpayers have not been disclosed.
Could GLP-1 Drugs Help You Live Longer?
Experts are intrigued by the theory. Here’s what early research suggests.
Could GLP-1 Drugs Help You Live Longer?
Experts are intrigued by the theory. Here’s what early research suggests.
AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
Edison Scientific and investment firm Population Health Partners are teaming up to leverage AI agents in drug discovery and development.
Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Positive results from the MULBERRY Phase III trial showed that efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy, demonstrated a statistically significant and clinically meaningful improvement in bone health in children (2 to
Rescheduling marijuana would put politics ahead of science
The Drug Enforcement Administration is considering a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act, which would recognize all cannabis products as havi…
Rescheduling marijuana would put politics ahead of science
The Drug Enforcement Administration is considering a proposal to move marijuana from Schedule I to Schedule III of the Controlled Substances Act, which would recognize all cannabis products as havi…
Patients can save thousands with drug coupons, but only if insurers honor them
Patients who rely on co-pay assistance from drugmakers are typically heavy users of health care for whom delays in treatment or worsening conditions can lead to higher costs, according to patient advocates.
States seek to lower drug prices by targeting the companies that manage them for health plans
TOPEKA, Kan. — As consumers worry about medication costs, states are trying to lower drug prices by reining in big companies that oversee prescription coverage for health insurers. Some of those companies, called pharmacy benefit managers, also own pharmacies, and one of them, CVS, has spent millions of dollars fighting
If a Lyme disease vaccine gets approved, how would it go over? We asked hunters
Drugmakers are working on a potential new shot to prevent the tick-borne illness. How might it fare in the era of vaccine skepticism?
States seek to lower drug prices by targeting the companies that manage them for health plans
Legislators across the U.S. are trying to lower prescription costs by reining in big companies that handle drug coverage for health insurers.
States seek to lower drug prices by targeting the companies that manage them for health plans
Legislators across the U.S. are trying to lower prescription costs by reining in big companies that handle drug coverage for health insurers.
Americans keep poisoning themselves with semaglutide, other weight loss drugs
These incidents became much more common after the FDA started approving GLP-1 drugs for chronic weight management in 2021.
Scientists infected a 'vagina on a chip' with gonorrhea — then cured it with a new antibiotic found by AI
To sift through 6 million molecules in pursuit of new gonorrhea treatments, researchers trained AI to select the best drug candidate and then tested it in a "vagina on a chip."
Morocco jails 29, including politicians and sports figures, in drug trial
Casablanca court delivers landmark verdict in 'Escobar of the Sahara' case: up to 12 years for top figures.
Medicare will soon offer some older Oregonians weight loss drugs for $50 a month. Here’s how it works.
Medicare has long excluded coverage of GLP-1s prescribed solely for weight loss.
Supreme Court rules in weedkiller cancer case
Dems want to unmask Eli Lilly's obesity drug user, a new genome-editing tool raises ethics questions, and more health news
Medical breakthroughs collide with the health system
The buzziest advances — like personalized gene therapies or AI-discovered drugs — may not deliver.
Trump nominates new top deputy to RFK Jr.
Chris Klomp, a 45-year-old tech entrepreneur, gained the president's confidence when he negotiated price cuts with drug companies.
Making Our Own Luck
We are cross-posting a piece that former NIH official Kris Willis wrote for Macroscience. Kris is now the President and Founder of the Woodley Park Institute, for which I’m a board member. Picking winners or hedging bets? Federal science agencies have long wrestled with the question of how to ensure their billions of dollars of grants and contracts result in maximum benefits for Americans. On the surface, it might seem that a goal-oriented, interventionist style of management would be the best policy: prioritize our most pressing problems and distribute funding accordingly.This top-down strategy creates a unique hazard, though: bad choices can send resources in the wrong direction, resulting in slow progress that impedes the delivery of tangible benefits to citizens. Moreover, if decision makers pursue an applied advance when the underlying scientific principles remain poorly understood, they risk costly failures and a loss of support for the research enterprise at large. Examples include Nixon’s 1971 War on Cancer, undertaken on the premise that a cure could be achieved in less than a decade, the drive to build an operational commercial fusion plant by the mid-1990s, and the National Plan to Address Alzheimer’s Disease, which failed to produce the effective treatments and prevention strategies promised by 2025. The contrasting laissez-faire approach is to hedge your bets. If the path to an advance is impossible to predict, then the wisest choice might be to distribute funding to as widely as possible. The main risk of this strategy is that spreading funding thinly may limit the resources available to the most promising research, resulting in the same negative outcomes as the interventionist approach: limited support for the most promising topics, slow progress, and delayed returns. In reality, at science agencies like the National Science Foundation and National Institutes of Health, program managers navigate between these two extremes, setting some funds aside to target high-priority areas and using the rest to cover the widest possible range of meritorious proposals. This middle path seems like the most rational way to proceed, but it still requires making choices. How much should be set aside for high priority topics? What should those topics be? How should we define merit? Expert opinion can provide a helpful guide, but leading experts can have remarkably different opinions about what matters and what should be prioritized. Moreover, experts and administrators alike can be risk averse, giving an edge to high-profile, well-established concepts. What’s really needed is a data-driven framework to help guide decision-making, one that doesn’t simply repackage prestige or incumbency. Recognizing breakthroughs years in advance Many breakthroughs fail to attract funding or recognition at the earliest stages of development. Katalin Karikó, for example, spent years struggling to win grants for work on mRNA that would eventually win her and Drew Weissman a Nobel Prize. Similar stories can be told about Jim Allison’s groundbreaking studies leading to the development of cancer immunotherapy, Stan Pruisner’s demonstration that prions can self-replicate without DNA, or Robin Warren and Barry Marshall’s proof that Helicobacter pylori, not stress, causes ulcers. Yet at some point, the scientific community recognizes and responds to transformative breakthroughs like these. How does that change happen? And what if science funders could identify the areas that are on the cusp of a breakthrough? Those questions led my collaborators and me to study how scientists responded to past breakthroughs. Based on patterns in that data, we developed a means of predicting future breakthroughs, using biomedicine as a proof of concept. It’s worth taking a moment to describe how our approach works. Briefly, our prediction process begins by grouping the 18 million or so peer-reviewed papers in PubMed, the authoritative database of biomedical research, into roughly 50,000 unique topics. A small subset of these topics are so widely acclaimed as breakthroughs that they have been recognized with a major prize like a Nobel or a Lasker Award. We theorized that studying the development of these outliers over time, especially before they gained acclaim, was the key to identifying future instances of them. After defining topics, we chose 21 representative breakthroughs and asked what they looked like before they won prestigious prizes. To answer that question, we re-ran our topic-mapping algorithm repeatedly, winding back the clock one year each time, stringing together the years to follow the progress of each field as it grew and advanced. We found that in each case, the years leading up to a discovery followed a pattern: a burst of papers on a new, rapidly evolving topic, many of which quickly became influential. These characteristics—the percent of papers that are new, the percentage of papers that are brought in from other topics, and the influence of each individual paper—can all be measured separately for any given topic. Together, they act as a predictive signal that is detectable an average of five years before a transformative discovery is made, and up to thirty years before the discovery receives a major prize. Scanning the current research landscape for topics that display this signal allows us to predict what work will likely produce a future breakthrough. Each year we analyzed includes four or five signals, a number that appears to have remained constant across a twenty year time frame. In their classic work on the sociology of science, Bruno Latour and Steve Woolgar established that the desire to participate in a major discovery is an important motivator for scientists as they consider whether they should take up (or abandon) a research problem. Although further work is needed, the simplest explanation for our results is that this behavior is widespread enough to detect at scale. A foundational advance, or something like it, draws the attention of scientists and causes them to change the direction of their research. They vote with their feet, staking their own reputation and careers by publishing on and citing the new idea. That upswell of interest is the foundation of our breakthrough signal. What kind of research does our model identify as a breakthrough? After building a model based on the patterns in our 21 preselected breakthroughs, we tested it by identifying all early signals of discovery from 1994 through 1997. Of the 18 signals we found in that time period, 17 can be traced forward in time to a breakthrough. Examples include super-resolution fluorescence microscopy (see the image above), the directed evolution of proteins and enzymes (Chemistry Nobel, 2018), and sequencing the human genome (National Medal of Science, 2008). The discovery of the role of leptin signaling in obesity is a particularly interesting case study. Around 1950, scientists noticed the existence of a type of lab mouse that suffered from a unique inherited form of obesity. When given the freedom to choose their own diet, these mice ate more than normal and preferred food that was high in fat. Researchers had few clues as to why the animals overate; early experiments pointed to the existence of a soluble ob factor found circulating in the bloodstream that regulated appetite, but its identity was unknown. In 1994, Jeffrey Friedman and colleagues identified and sequenced the ob gene, noting that the protein it encoded appeared to fit the profile of a circulating factor. A year later, a trio of high-profile publications demonstrated that ob was a hormone that regulated body weight and fat deposition by regulating appetite. One of these was co-authored by Friedman, who christened it leptin from the ancient Greek word for thin. Using our model, the data from 1996 make it clear this advance would become a breakthrough. Scientists had flocked to study the biology of the new hormone, generating the flurry of new papers and citations required to produce a signal. One of these demonstrated that serum leptin concentrations reflected the amount of adipose tissue in the human body, providing clinical validation of the earlier mouse studies. Before the identification of leptin, scientists were unable to point to a specific molecule that controlled appetite and adiposity, so that it was impossible to rule out non-physiological causes of obesity; its characterization fundamentally changed our concept of weight gain. In 2010, Friedman and fellow pioneer Douglas Coleman were awarded a Lasker for the discovery. Our work also identifies breakthroughs in clinical practice and behavioral and social sciences, even though these areas are less likely to draw the attention of major prize committees. One example that falls into this category is the introduction of endovascular aneurysm repair, a minimally invasive surgical procedure for the treatment of abdominal aortic aneurysm, a leading cause of death among Americans over the age of 65. Relative to the previous standard of care, it reduces in-hospital mortality by almost four-fold. In 2017, Timothy Chuter received the American College of Surgeons’ prestigious Jacobsen Innovation award for his multiple refinements to the technique. Another under-recognized breakthrough identified by our model is the development of standardized survey instruments to assess the quality of life for HIV+ patients. The antiretroviral cocktails introduced in the mid-1990s reduced AIDS mortality, but treatment came with serious side effects. The new evaluations showed that patients whose disease progressed had worse physical functioning than Americans with other chronic diseases, while those who were asymptomatic maintained a health-related quality of life on par with the overall US population. This evidence made it possible for patients and activists to argue that even in the absence of a total cure, and in spite of the side effects, alleviation of symptoms was a worthwhile priority for clinicians. My colleagues and I have failed to identify any significant recognition for the physicians and health policy experts who pioneered this advance, although in 2016, researchers called for the World Health Organization to set targets for good health-related quality of life as part of its framework to end the AIDS pandemic. From forecasting to funding How should science funders use our predictions? Any serious discussion of what we should do with this new capability needs to begin with an understanding of its limitations. We can’t (and shouldn’t) invest all of our resources in the small number of topics predicted to produce breakthroughs. Innovative new fields are born from existing ones; they rarely arise de novo. If funders don’t maintain a diverse portfolio, the breakthroughs of tomorrow will have no antecedents. Think of this as eating the seed corn, or killing the goose that lays the golden egg. There are also multiple goals of funding beyond basic scientific discovery, including translating discoveries into clinical practice, developing new technologies, supporting economic development, and training new scientists. The investments needed to accomplish these goals are likely different from those required to support emerging breakthroughs. Finally, we must be aware that we may not capture every instance of a breakthrough. The concept is fuzzy, and not every significant discovery is recognized with a major award. Further, breakthroughs are rare, meaning that our dataset is, by necessity, small. This makes formal estimates of accuracy challenging. Although our overall success rate appears to be high, any one signal may turn out to be a false positive. We found one apparent example: the development of the third generation COX-2 inhibitors, Vioxx and Celebrex, which were much celebrated in the early 2000s as effective but non-addictive pain relievers, meets all the algorithmic criteria of a breakthrough. Five years after it received FDA approval, researchers demonstrated that Vioxx was associated with serious cardiovascular complications, and the manufacturer voluntarily pulled the drug from the market. Celebrex remains available, although like other NSAIDs, it carries an FDA warning for increased cardiovascular risk. Decision makers who were overly focused on the breakthrough potential of this research might have wasted substantial resources nurturing an area that ultimately proved to be a failure—but so would those who relied on expert opinion at the time. That said, the potential benefits of funding the next mRNA vaccine or cancer immunotherapy years earlier than we might have are large. When we can’t assume the outcome of an action, it’s worth conducting an experiment. Can targeted support for areas that are poised to produce a breakthrough increase the return on scientific investment without cannibalizing future advances? With the necessary administrative infrastructure in place, conducting this experiment would be straightforward. First, identify all the breakthrough signals between 2018 and 2023, select half at random, and commit to a decade of investment. For biomedicine, a six year window should yield about 30 topics with the potential to produce a breakthrough. Providing strong support to half of these might be accomplished for $300 million a year. That’s roughly half of the recent annual budget of the NIH Common Fund or around 20% of the fiscal year 2025 budget for ARPA-H. After five years, then again at ten, compare to see which group — the one that was actively managed, or the control — produced more breakthroughs, and on what timescale. Although we used biomedicine as an example, the same experiment could just as well be run for physics, materials science, or any other discipline. Any attempt to undertake such an experiment should keep three points top of mind. First, we can predict the topic of future breakthroughs, but the people and vision for how to move the work forward are still important. In practice, this means success requires active program managers with the expertise to develop the science and the authority to do so, including by recruiting investigators. Second, we would be wise to learn from the failures of past attempts to fund transformative research. High among these are funding modestly repackaged work, confusing the genuinely novel with the merely unfamiliar, and relying too much on incumbent investigators. All of these risks can be mitigated by thoroughly and intelligently integrating high quality data into portfolio management. Finally, we need to have patience. Even with strong funding support, producing a breakthrough takes time. If supporting breakthroughs is the best way to nurture the birth of new fields, we also need to accurately describe and properly manage the other two stages, so that we invest wisely throughout the productive lifetime of ideas and divest once they reach the point of diminishing returns. We would benefit from more study of all of these phases, especially the transition from one to another. More research could answer questions like: When does a breakthrough become an established field? How do the availability of funding, the size and characteristics of the available workforce, and the accumulation of evidence that disagrees with prevailing models affect a field’s decline? Exactly how do old ideas give birth to new ones, and can we speed up the process? The more we understand about the dynamics of scientific progress, the better we can maximize the odds that our curiosity leads to results. I’d call that finding a way to make our own luck.
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
It's one thing to design a pharmaceutical drug. It's another to know if and why it actually works; not on paper or in a computer model, but inside the chaotic world of living systems, where proteins twist ...
Health Subcommittee Markup of 15 Bills Addressing Illicit Drugs and Health Care Price Transparency
The Committee on Energy and Commerce is the oldest standing legislative committee in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee.
CMS projects national health spending grew to $5.7 trillion in 2025
National health spending is projected to have reached $5.7 trillion in 2025, up 7.3% from 2024, according to an analysis by the Centers for Medicare & Medicaid Services published yesterday by Health Affairs. It marks the third consecutive year of growth greater than 7%. CMS projects growth to continue in 2026 due to continued demand for high-cost retail prescription drugs, mostly from individuals with Medicare and private insurance.
Scientists measure hidden quantum forces that could power a new generation of pharmaceutical drugs
Researchers invent a laser technique that reveals the hidden forces shaping proteins, advancing a future of precision medicine engineered with quantum precision.
FDA-approved drug may finally help immunotherapy defeat rare liver cancer
Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.
Hims' obesity drug business may get boost as employers drop coverage
Telehealth provider Hims and Hers Health may get a boost next year from employers dropping coverage of weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo to rein in costs, investors and analysts say.
U.S. health spending rose sharply in 2025, thanks to GLP-1 use and more care
People are getting more care and using lots of GLP-1 drugs, fueling a sharp increase in health care spending.
This health data provider could benefit as AI reshapes drug research
Harvey Stober, senior equity analyst and correspondent at CNBC, explains why this healthcare company could benefit from artificial intelligence reshaping the drug industry thanks to its treasure trove of data.
FSU computational scientist helps advance targeted drug-delivery systems using coding, modeling
A Florida State University computational scientist is paving the way for future medical breakthroughs by developing mathematical models and simulations to
How a $0 co-pay saves billions
Bringing down drug costs is the first step to improve health care affordability.
People on GLP-1 medications are exercising less
A new study found that people using weight-loss drugs are doing less exercise, despite feeling healthier. Here's how muscle mass and bone density are affected.
Trouble getting weight loss drugs covered by insurance? Here's what to know
If your doctor prescribes a GLP-1 medication for weight loss but your insurance won't cover it, you have options.
Health Brief: FDA signals reset in drug reviews
Plus: The data behind China’s biotech surge
Health officials launch clinical trial reforms to counter China threat
The Food and Drug Administration (FDA) on Monday launched a new initiative to speed up early-stage clinical trials as part of an effort to reduce development timelines and reverse a growing trend o…
FDA to launch pilot program to speed up early-stage clinical trials
Federal health officials aim to speed up drug development and better compete with China.
“Criminal Approach to Politics”: Trump Ally Abelardo de la Espriella Wins Colombian Presidency
Right-wing Trump ally Abelardo de la Espriella has clinched a narrow victory in Sunday’s runoff presidential election in Colombia, defeating leftist Senator Iván Cepeda, an ally of current President Gustavo Petro. De la Espriella ran a fearmongering, “tough-on-crime” campaign, promising to build mega-prisons inspired by El Salvador’s authoritarian President Nayib Bukele, to bomb “narcoterrorist camps” and to abandon Petro’s peace efforts. His reported victory is also a win for U.S. President Donald Trump, whose administration is waging an intensifying “war on drugs” across Latin America, targeting left-wing leaders like Petro with false allegations and threats of military intervention. “De la Espriella clearly represents a criminal approach to politics: lying, propaganda, coordination and collusion with criminal narcotrafficking, restriction of rights, and money laundering,” says longtime Colombian activist Manuel Rozental. With his victory, says Rozental, “We expect to have military operations and a U.S. intervention within the country. We expect to have human rights abuses. We expect to have militarization. And it’s all for the extraction of resources and the link of drug trafficking to the U.S. government, U.S. interests and global mafia.”
Axios-Ipsos poll: Health affordability is shaping the midterms
About half of Americans say measures aimed at drug and insurance affordability will probably influence who they'll vote for.
Colombia's presidential runoff election will decide how the country continues to tackle drug trafficking
As Colombia's government makes modest gains in disarming guerrillas, voters head to a runoff where the frontrunner vows to abandon peace talks and escalate a hardline war on drug traffickers.
Cities and Schools Are Testing Wastewater for Illicit Drugs
The White House recently endorsed monitoring sewage for evidence of drug use. Critics fear such efforts could violate privacy and stigmatize neighborhoods.
Bigger, fewer, tougher: the new era of China-US biotech partnerships
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
Daveigh Chase's mother says late 'The Ring' star struggled with addiction after back injury: 'She was completely gone'
Daveigh Chase's mother said that 'drugs took hold of' the late 'Lilo & Stitch' actress after she was prescribed painkillers for a back injury she sustained in a motorcycle accident around 2016.
Opinion | We Need to Keep Funding Weird Science
Science turned a serendipitous finding about lizard venom into one of the most important drugs of the century, but that type of research is getting harder to do.
Should everyone be on GLP-1s? What science actually tells us (and doesn't) about the broader health benefits
The laundry list of possible health benefits from GLP-1 drugs seems to get longer by the day, from cancer prevention to combating addiction. But while there’s no question these medications show immense promise beyond their use for diabetes and weight loss, science is still catching up.
Popular weight-loss drugs linked to unexpected male fertility benefit
GLP-1 drugs like semaglutide and liraglutide do not appear to suppress male hormones and may boost fertility in obese men, new research suggests.
Ozempic changed obesity treatment, but experts say the real revolution is next
The obesity treatment landscape is changing fast, with GLP-1 drugs opening the door to more effective care than ever before. Experts now envision a future where medications, minimally invasive procedures, surgery, and precision medicine work together to deliver better long-term results.
MUSC Health passes $10B budget, reflecting growth in drugs and population
Medical University of South Carolina and its hospitals and physicians will have a budget that tops $10 billion next fiscal year, driven by the cost of drugs and a growing population in the state.
Assertio completes $166M merger with Zydus following bidding war
The deal leaves Lake Forest-based Assertio, which specializes in oncology drugs, as a wholly-owned subsidiary of Zydus Lifesciences.
Major grocery operator on the hook for $40M over pharmacy monkey business; $6M windfall for whistleblower
One of the largest food retailers in the world—and the fourth biggest in this country—got itself into hot water with the U.S. Department of Justice for allegedly cheating on drug prices it charges to federal healthcare programs.
Analysis of 352 probiotic supplements finds mismatched microbes across marketed health benefits
Probiotic supplements found in drugstores nationwide contain an assortment of microbes sold for specific health purposes despite limited understanding of the microbes' connections to their marketed use, ...
The Drug That Bought My Father More Time Didn't Happen by Accident
Behind every medical breakthrough are decades of research — and decisions being made right now could determine which discoveries come next.
Supreme Court limits power of federal government to disarm drug users
The Supreme Court Thursday curbed the power of the federal government to disarm a frequent marijuana user, limiting the scope of a law enacted during the 1960s to keep weapons out of the hands of Americans who regularly use drugs.
Alzheimer's Drug Discovery Foundation Begins Search for New Chief Science Officer as Co-Founder Dr. Howard Fillit Transitions to Emeritus Role
/PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) today announced that its Co-Founder and Chief Science Officer (CSO), Dr. Howard Fillit, is...
NM spent nearly $844M on behavioral health, but 'investment is not yet matching the outcome'
New Mexico has spent $843.5 million since 2022 to rebuild state’s behavioral health system but still faces problems.
A surprising discovery reveals the kidney has a secret backup system
Scientists at Mayo Clinic have uncovered a surprising new way the kidneys conserve water, revealing a hidden backup system that works independently of the hormone long believed to control the process. The discovery emerged when researchers testing an old drug called probenecid expected it to worsen polycystic kidney disease (PKD) but found it actually slowed cyst growth instead.
More than 11K bottles of blood pressure drug recalled
Certain lots of a popular diuretic have been recalled due to concerns about the drug's effectiveness.
Abarca Health And LucyRx To Merge Into Alternative To Big Three PBMs
Abarca Health and LucyRx - two independent pharmacy benefit managers - have agreed to merge asregulators and the public seek a better price on prescription drugs.
Ozempic and Wegovy linked to surprising drop in violent behavior
A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress that cause and effect have not been proven.
CMS proposes codifying, strengthening Medicare drug price negotiations
Presented by Philip Morris International{beacon} Health Care Health Care PRESENTED BY The Big Story Protect Our Care highlights adverse effects of GOP cuts on hospitalsDemocratic-…
The Courtroom Battle Over Baby Formula Isn’t About Science
A jury in a Cook County, Illinois, court awarded families $70 million in April after concluding that infant formula caused a devastating illness in premature babies. However, that conclusion hinged on a scientific theory that lacks validated evidence. While the U.S. Food and Drug Administration said its recent study of chemical contamination in infant formula produced by Abbott Laboratories … Continue reading "The Courtroom Battle Over Baby Formula Isn’t About Science"
Cell and gene therapy's next challenge is not the science, it's everything else
The field's foundational biology is no longer the limiting factor. What comes next depends on whether the industry can build the manufacturing, commercial, and clinical infrastructure to match what the science already knows how to do.
Rhode Island health insurers seek double-digit hikes
'Unsustainable’ increases reflect higher cost of prescription drugs and fewer people on the state health exchange.
Gross Medicaid Prescription Drug Spending
State level data on Gross Medicaid Prescription Drug Spending from KFF, the leading health policy organization in the U.S.
Adaptive plots splitting Pfizer-partnered drug discovery unit from diagnostics business
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses,
Central Florida counselor discusses connection between mental health and GLP-1 weight-loss drugs
Licensed mental health counselor Shantala Boss explores the connection between GLP-1 medications, disordered eating, and body image concerns.
These projects help companies leverage AI to tackle pressing business needs
Whether helping to fight hackers or speeding up drug discovery, these World Changing Ideas are giving businesses helpful AI solutions.
GLP-1 and weight-loss drugs: How fast-track health solutions are reshaping FMCG
GLP-1 weight-loss drugs are reshaping FMCG as health, body control, and self-optimization trends redefine consumer behaviour across Europe.
Why healthcare stocks are primed to outperform the market: 2 firms
UBS listed three reasons they like the sector, starting with GLP-1 weight-loss drugs.
Alfredo sauce distributed to dozens of states recalled due to potential salmonella contamination
The sauce was voluntarily recalled by the supplier because it contained a dry milk powder ingredient that was possibly contaminated with salmonella, according to a U.S. Food and Drug Administration enforcement report.
Indiana attorney general targets abortion pill mifepristone as water risk. Health experts dispute the claim
Indiana’s Attorney General joined 13 other states to call for the EPA to classify the abortion inducing drug mifepristone as a water contaminant, arguing it could pose a health risk. Health experts say there’s no evidence for his claims.
SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
Key Facts: FDA has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of...
Express Scripts sues Tennessee over PBM law that would close specialty pharmacy
The company called the state’s regulation of pharmacy benefit managers “shortsighted,” as it would force the closure of Accredo, a specialty drug dispensary that supplies drugs it says aren’t available anywhere else in the state.
Somerset public health director calls for safe drug-taking space
Alison Bell says the space could also test the substances and help people if they overdose.
Amid confusion over Pfizer's emergency penicillin program, newborn is diagnosed with preventable syphilis
Congenital syphilis should be preventable. An Arizona case shows how drug shortages and procedural hurdles are fueling a growing public health crisis.
'Risk of electrical shock' prompts recall of imaging systems
A handful of fluoroscopy units manufactured by GE HealthCare are the subject of a new recall by the U.S. Food and Drug Administration.
Asthma drug helps woman reclaim her health
Carly Silvester said her quality of life was now "unbelievable" thanks to the treatment.
Want obesity drugs covered by insurance? Telehealth companies have a big say
Telehealth companies offer lifestyle support so people taking obesity drugs can have the most success losing weight. But employers also want the telehealth providers to limit spending on the drugs.
People taking GLP-1 weight loss drugs like Ozempic started moving less
People taking popular weight-loss drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound may be losing pounds, but they could also be moving less. Researchers analyzing Fitbit data found that daily step counts and exercise levels dropped after people started these medications, despite successful weight loss. Because the drugs can reduce muscle mass along with fat, the decline in physical activity raises concerns about preserving strength and long-term health.
GLP-1 Drugs May Protect Against Cancer— Here’s What That Means For Public Health
New research suggests GLP-1 drugs could reduce cancer risk. A doctor breaks down how that could change public health in the future.
Changes to the NC State Health Plan will make retirees pay more. Here’s what it means for you
Retirees on the state’s Medicare Advantage plans will pay more for hospital stays, specialist visits and some drugs next year.
Scientists Race to Test Treatments as Ebola Outbreak Widens
Trials are beginning on several drugs that have shown promise in preliminary studies against the virus that is causing the current outbreak.
Stanford scientists regrow lost cartilage and reverse arthritis in major breakthrough
A new treatment that blocks an aging-related protein restored lost cartilage in old mice and helped prevent arthritis after knee injuries. Human cartilage samples showed similar signs of regeneration, raising hopes for a future drug that could repair joints instead of replacing them.